New Fate employee gets 7,260 stock units vesting over 4 years
Fate Therapeutics (NASDAQ: FATE) announced the grant of 7,260 restricted stock units (RSUs) to a new non-executive employee on April 1, 2026. This inducement award, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4), will vest over four years, with 25% vesting annually subject to continuous employment. This aligns with the company's recent practice of utilizing such equity grants for new hires, a routine HR activity within the biotechnology sector.
IPSC Therapy Market Booming with Rapid Growth Through 2033 | Fate Therapeutics • Bluebird Bio • Celyad
Coherent Market Insights has published a report titled "iPSC Therapy Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033." The report offers an in-depth analysis of market competition, geographic distribution, and growth potential, covering industry performance, success factors, risk assessment, and financial details. It aims to provide comprehensive insights for entrepreneurs, investors, researchers, and business strategists in the dynamic iPSC Therapy Market.
Fate Therapeutics Announces New Employee Inducement Award
Fate Therapeutics announced a new employee inducement award, granting restricted stock units to a non-executive employee. This move highlights the clinical-stage biopharmaceutical company's strategy to expand its workforce and advance its pipeline of iPSC-derived cellular immunotherapies for cancer and autoimmune diseases. The RSUs will vest over four years, demonstrating the company's commitment to long-term employee retention.
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. announced a new employee inducement award consisting of restricted stock units (RSUs) representing 7,260 shares of its common stock to a newly hired non-executive employee. This grant, approved by the Compensation Committee, is made under the Company’s Amended and Restated Inducement Equity Plan and complies with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually, contingent on continuous employment.
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. announced a new employee inducement award of restricted stock units (RSUs) representing 7,260 shares to a newly-hired non-executive employee on April 1, 2026. This award, approved by the Company's Compensation Committee and granted under its Amended and Restated Inducement Equity Plan, is an inducement for the employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually, contingent on continuous employment.
Fate Therapeutics Inc Stock: Pioneering iPSC Cell Therapies Amid Biotech Volatility
Fate Therapeutics Inc is a leader in iPSC-derived therapies, focusing on oncology and autoimmune treatments, utilizing its proprietary technology for scalable manufacturing of off-the-shelf natural killer and T-cells. The company's pipeline includes lead programs like FT819 for B-cell malignancies and FT522 for autoimmune conditions, positioning it as a high-risk, high-reward opportunity for North American investors in the competitive cell therapy sector. Despite operating at a cash burn typical for clinical-stage biotechs, its strategy emphasizes allogeneic products and seeks to overcome manufacturing bottlenecks faced by larger players, with clinical milestones serving as key catalysts for share value.
FATE Should I Buy
This analysis of Fate Therapeutics Inc (FATE) advises against purchasing the stock for beginner long-term investors due to weak financial performance in Q4 2025, a lack of significant positive catalysts, and bearish technical indicators. While recent analyst upgrades from H.C. Wainwright and Wedbush suggest future potential based on clinical trial results for FT819, the current financial and technical data point to a high probability of short-to-medium term decline.
Fate Therapeutics Inc Stock: Pioneering iPSC Cell Therapies Amid Biotech Volatility
Fate Therapeutics Inc is a leader in developing induced pluripotent stem cell (iPSC)-derived therapies for oncology and autoimmune diseases, positioning itself as a high-risk, high-reward opportunity in the cell therapy sector. The company's proprietary iPSC platform allows for scalable manufacturing of off-the-shelf NK and T-cells, aiming to overcome limitations of autologous therapies and reduce costs. While facing competition, Fate Therapeutics differentiates itself with its focus on iPSC-derived NK and T-cells, and its pipeline, which includes lead programs like FT819 for B-cell malignancies and FT522 for autoimmune indications, offers potential for significant breakthroughs.
Fate Therapeutics (NASDAQ:FATE) Share Price Passes Below 200-Day Moving Average - Here's What Happened
Fate Therapeutics (NASDAQ:FATE) stock recently fell below its 200-day moving average, trading at $1.13, marking a significant technical event. Analysts hold a mixed view with an average "Hold" rating and a target price of $4.10, despite the company reporting deeply negative margins and anticipated negative EPS for the current year. Institutional investors own a substantial portion of the stock, with some increasing their positions in the latest quarter.
Vanguard (FATE) reports 0 shares after internal realignment
The Vanguard Group has filed an amended Schedule 13G/A for Fate Therapeutics (FATE), reporting zero beneficial ownership of common stock. This change follows an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report their ownership separately, as per SEC Release No. 34-39538. The filing was signed on March 26, 2026, indicating a procedural change in reporting structure rather than a sell-off.
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of "Hold" from Brokerages
Fate Therapeutics, Inc. (NASDAQ:FATE) has received a consensus "Hold" rating from brokerages, based on analyst reports with an average 1-year target price of $4.10. The company, which trades around $1.10, is heavily institutionally owned at 97.54%, with several hedge funds increasing their positions. Fate Therapeutics remains unprofitable, with analysts forecasting an EPS of -1.63 for the current fiscal year, as it continues to develop cellular immunotherapies for cancer.
Fate Therapeutics Inc stock faces analyst caution amid biotech pipeline scrutiny
Fate Therapeutics Inc is receiving mixed signals from Wall Street analysts, with a consensus leaning towards "hold" ratings despite an implied 100% upside from current price levels. The company, specializing in iPSC-derived cellular immunotherapies, is navigating restructuring efforts and pipeline development, including its key asset FT819, a Phase 1 CAR T-cell therapy. European investors are eyed for potential high-risk, high-reward opportunities given the company's innovative platform and strategic leadership changes, though significant clinical and financial risks remain.
Fate Therapeutics Inc stock faces analyst caution amid biotech pipeline scrutiny
Fate Therapeutics Inc (FATE) is navigating a challenging biotech landscape, with analysts issuing "hold" ratings and modest price targets despite the company's innovative induced pluripotent stem cell (iPSC) therapies. The company recently underwent restructuring and leadership changes to streamline operations and extend its cash runway, focusing on key assets like FT819 for B-cell malignancies. While the sector faces headwinds, Fate's off-the-shelf iPSC platform offers potential long-term benefits for personalized medicine, attracting interest from German-speaking investors seeking high-risk, high-reward opportunities.
FATE SEC Filings - Fate Therapeutic 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors and traders to access official regulatory documents for Fate Therapeutics (Ticker: FATE), including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It highlights key events such as financial results, clinical data updates for FT819, workforce restructuring, and changes in executive leadership. The platform also offers AI-powered summaries of these filings to quickly identify important details.
FATE SEC Filings - Fate Therapeutic 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Fate Therapeutics (FATE) SEC filings, including 10-K, 10-Q, and 8-K reports. It highlights how these regulatory documents offer critical information on the company's financial condition, clinical programs, and corporate actions, with AI-powered summaries to help investors quickly identify key updates. The site also includes current stock price and market capitalization data for Fate Therapeutics.
Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at Conference
Fate Therapeutics discussed the manufacturing and clinical strategy for its off-the-shelf CAR T-cell therapy, FT819, at a Leerink Partners conference. The company highlighted FT819's scalable manufacturing process, its engineered safety profile, and its focus on autoimmune diseases, particularly lupus nephritis. Fate plans to initiate a potential registration-enabling Phase II single-arm trial for lupus nephritis in the second half of the year, while also developing next-generation multiplex-edited CAR T candidates.
Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) reported a narrower-than-expected loss in Q2, while its revenue surpassed analyst estimates. The company posted a loss of $0.51 per share, beating the Zacks Consensus Estimate of a $0.54 loss. Revenues for the quarter came in at $9.7 million, exceeding expectations of $8.11 million.
FATE: FT819 shows promising efficacy and safety in lupus nephritis, with pivotal trials set for later this year
Fate Therapeutics' CAR T-cell therapy, FT819, is showing promising early efficacy and safety in lupus nephritis, leading to plans for a pivotal phase II trial in the second half of 2026. The therapy offers advantages like off-the-shelf availability, outpatient administration, and scalable manufacturing. The company is also developing next-generation products for broader autoimmune indications.
Fate Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout
Fate Therapeutics has recently experienced a Golden Cross, where its short-term moving average crossed above its long-term moving average, indicating a potential bullish trend. While technical indicators like MACD and KST show bullish momentum, the stock has strong one-year (37.61%) and year-to-date (52.66%) performance, despite significant declines over the longer term. Investors are closely watching how these technical signals and recent performance trends will evolve.
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
Fate Therapeutics, Inc. announced its management will participate in a fireside chat and host investor meetings at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026, in Miami, Florida. The fireside chat is scheduled for 9:20 AM ET and a live webcast will be available on the company's website, with an archived replay accessible for 90 days. Fate Therapeutics is a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. announced the grant of restricted stock units representing 50,700 shares to three new non-executive employees on March 2, 2026. These inducement awards were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) and will vest over four years. The company is a clinical-stage biopharmaceutical firm focused on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases.
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
The cell therapy market is experiencing significant growth, projected to surpass $8.2 billion in 2026, driven by clinical advancements and manufacturing innovations. Companies like Avaí Bio, FibroBiologics, Fate Therapeutics, Mesoblast, and Longeveron are at the forefront of developing next-generation cell-based treatments for various conditions, including aging, osteoporosis, autoimmune diseases, and inflammatory disorders. The sector's expansion is supported by an increasing number of FDA-approved products and the development of scalable manufacturing platforms.
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
Fate Therapeutics, a clinical-stage biopharmaceutical company, announced its management will participate in the Leerink Partners 2026 Global Healthcare Conference. They will host investor meetings and a fireside chat on March 9, 2026, in Miami, Florida. A live webcast of the fireside chat will be available on the company's website.
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
Fate Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the Leerink Partners 2026 Global Healthcare Conference. Management will host a fireside chat and investor meetings on Monday, March 9, 2026, in Miami, Florida. A live webcast of the fireside chat will be available on the company's website.
FATE Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Fate Therapeutics (FATE) for fiscal year 2025, including income statement, balance sheet, and cash flow data, along with key financial ratios. It highlights the company's weak financial health with an operating margin of -2222.4%, a revenue decline of 51.2%, and a low Piotroski F-Score of 1 out of 9. Despite low debt and strong liquidity, the company shows low earnings quality due to being accrual-driven and has an estimated cash runway of only about 5 months.
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Fate Therapeutics announced its Q4 and full-year 2025 financial results, highlighting significant progress in its off-the-shelf CAR T-cell therapies. Key achievements include outpatient treatment capabilities for FT819 in autoimmune diseases, promising early clinical activity for FT836 in colorectal cancer without conditioning chemotherapy, and a projected operating runway through 2027 with $205 million in cash. The company is advancing its clinical trials and expanding global reach for its innovative iPSC-derived therapies.
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and Fate Therapeutics (FATE)
Analysts have provided insights on two healthcare companies, BioCryst (BCRX) and Fate Therapeutics (FATE). TD Cowen's Stacy Ku maintained a Buy rating on BioCryst with a $30.00 price target, while the overall consensus for BioCryst is a Strong Buy. For Fate Therapeutics, TD Cowen's Tara Bancroft maintained a Hold rating, with the Street consensus suggesting a Moderate Buy.
Biotechnology company Fate Therapeutics Inc announced that its current cash reserves are sufficient to sustain company operations until the end of 2027.
Fate Therapeutics Inc, a biotechnology company, has announced that its current cash reserves of $205 million will fund operations until the end of 2027. This financial stability will support the advancement of multiple preclinical and clinical projects, including CAR-NK and iPSC-derived cell therapies, ensuring continued investment in new drug development.
Earnings Summary: Fate Therapeutics Q4
Fate Therapeutics (NASDAQ: FATE) announced its Q4 earnings on Thursday, February 26, 2026, reporting an EPS of $-0.27, missing estimates by 0.0%. Revenue for the quarter was down $491 thousand compared to the same period last year. The company's stock symbol is FATE.
Fate Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview
Fate Therapeutics Inc. is expected to report an earnings loss of 28 cents per share. This information comes from a Refinitiv earnings preview.
Fate Therapeutics FY 2025 Loss Reduction Tests Bullish Narratives On Path To Profitability
Fate Therapeutics concluded FY 2025 with a net loss of US$136.3 million and an EPS loss of US$1.15, despite a reduction in losses compared to FY 2024. While revenue is projected to grow significantly, the company is expected to remain unprofitable for the next three years, challenging bullish narratives. The stock trades at a premium P/S multiple of 27.1x, which critics argue is high given its ongoing unprofitability and forecasted earnings declines.
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Fate Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting significant progress in its clinical programs. The company reported successful outpatient treatment with FT819 off-the-shelf CAR T-cell therapy for autoimmune diseases and early clinical activity for FT836 in colorectal cancer without conditioning chemotherapy. Fate Therapeutics also confirmed an operating runway through year-end 2027, supported by $205.1 million in cash and a 30% reduction in operating expenses.
Biotechnology company Fate Therapeutics Inc announced that its current cash reserves are sufficient to sustain company operations until the end of 2027.
Fate Therapeutics Inc., a biotechnology company, has announced that its current cash reserves of $205 million are sufficient to fund its operations until the end of 2027. This financial stability will enable the company to advance multiple preclinical and clinical stage projects, including CAR-NK and iPSC-derived cell therapies, ensuring continued investment in critical new drug development.
FATE THERAPEUTICS INC SEC 10-K Report
Fate Therapeutics Inc. has released its annual 10-K report, detailing financial highlights including collaboration revenue of $6.6 million and a net loss of $(136.3) million. The report outlines business highlights such as their iPSC-derived cellular immunotherapy pipeline, manufacturing facilities, and clinical trials for FT819 and FT825. The company faces significant challenges and risks related to clinical development, regulation, and market acceptance but plans to advance its pipeline and manage capital through strategic partnerships and financing activities.
Fate Therapeutics: Fourth Quarter Earnings Overview
Fate Therapeutics incurred a net loss of $32.4 million, or $0.27 per share, in the fourth quarter, aligning with analyst projections. The biotechnology company generated $1.4 million in revenue for the quarter. For the full fiscal year, Fate Therapeutics reported a total loss of $136.3 million ($1.15 per share) and $6.6 million in annual revenue.
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Fate Therapeutics (NASDAQ: FATE) announced its financial results for the fourth quarter and full year 2025, along with significant business updates. The company highlighted advancements in its off-the-shelf CAR T-cell therapies, including successful outpatient treatment for autoimmune patients with FT819 and early anti-tumor activity of FT836 in colorectal cancer without conditioning chemotherapy. Fate Therapeutics projects an operating runway through year-end 2027, supported by $205.1 million in cash and investments, and a 30% reduction in operating expenses in 2025 compared to 2024.
Fate Therapeutics (NASDAQ: FATE) cuts 2025 expenses, extends cash runway
Fate Therapeutics Inc. (NASDAQ: FATE) announced its fourth-quarter and full-year 2025 financial results, reporting a narrowed net loss of $136.3 million and significantly reduced operating expenses to $154.4 million. The company projects an extended cash runway through year-end 2027, supported by $205.1 million in cash and investments and a 30% reduction in operating expenses. Operationally, Fate Therapeutics made strides in its off-the-shelf CAR T-cell pipeline, with advancements in FT819 for autoimmune diseases, including outpatient treatment, and early clinical activity for FT836 in colorectal cancer.
Fate Therapeutics (FATE) to Release Earnings on Wednesday
Fate Therapeutics (NASDAQ:FATE) is scheduled to release its Q4 2025 earnings before market open on Wednesday, March 4th, with analysts expecting an EPS of ($0.27) and revenue of $1.198 million. The biopharmaceutical company, which develops cellular immunotherapies, currently holds a consensus "Hold" rating from analysts with an average price target of $3.92. Institutional investors own a significant portion of the stock, with recent changes in their holdings.
FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation
Kaskela Law LLC has initiated an investigation into Fate Therapeutics, Inc. (NASDAQ: FATE) on behalf of long-term investors following an amended securities fraud complaint. The complaint alleges that Fate made false statements regarding its collaboration with Janssen Pharmaceuticals, which was later terminated, causing Fate's stock to drop over 61% in one day. The firm is seeking to determine if Fate's board breached fiduciary duties and encourages affected shareholders to contact them.
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
The report "IPSC-derived NK Cells Pipeline Insight 2026" from DelveInsight covers clinical developments in iPSC-derived NK cell therapies, highlighting over 12 companies and 15 pipeline drugs. Key players like Century Therapeutics and Fate Therapeutics are advancing treatments for autoimmune disorders, lymphomas, and other cancers. The report emphasizes the potential of iPSC-derived NK cells as a scalable, off-the-shelf option for next-generation cancer immunotherapies.
Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving Average - What's Next?
Fate Therapeutics (NASDAQ:FATE) shares recently crossed above their 50-day moving average, trading at $1.12 with significant volume. The company, which develops cellular immunotherapies, slightly surpassed its quarterly earnings and revenue expectations but remains unprofitable. Analyst consensus on the stock is "Hold" with an average target price of $3.92, while institutional investors maintain a substantial ownership of 97.54%.
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts
Nine analysts have issued a consensus "Hold" rating for Fate Therapeutics, Inc. (NASDAQ:FATE), with an average 12-month price target of $3.92. The biopharmaceutical company's shares are trading at $1.19 with a market cap of $137.3 million, and it reported negative earnings with a P/E ratio of -0.90. Institutional investors hold approximately 97.54% of the stock.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. announced new employee inducement awards in accordance with Nasdaq Listing Rule 5635(c)(4). A newly-hired non-executive employee received non-qualified stock options for 120,000 shares and restricted stock units for 90,000 shares. These grants, approved by the Compensation Committee, are designed to vest over four years, contingent on continuous employment.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. (NASDAQ: FATE) announced that it granted inducement awards to a newly-hired non-executive employee on February 1, 2026. The awards include non-qualified stock options for 120,000 shares and restricted stock units (RSUs) representing 90,000 shares, as approved by the Compensation Committee. These grants are part of the Company's Amended and Restated Inducement Equity Plan and comply with Nasdaq Listing Rule 5635(c)(4).
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. announced the granting of inducement awards to a newly-hired non-executive employee on February 1, 2026. These awards include non-qualified stock options for 120,000 shares and restricted stock units for 90,000 shares, approved under Nasdaq Listing Rule 5635(c)(4). The grants are part of the Company’s strategy to attract new talent and will vest over four years, subject to continuous employment.
The Truth About Fate Therapeutics Inc: Is This Biotech Underdog About To Explode Or Implode?
The article discusses the speculative nature of Fate Therapeutics Inc (FATE), a biotech company developing off-the-shelf cell therapies for cancer and immune disorders. It highlights the company's high risk-reward profile, significant stock volatility, and ongoing need for funding, cautioning potential investors to conduct thorough research beyond viral social media trends. The author concludes that FATE is a "speculative cop" only for investors who are prepared for substantial risk, volatility, and extensive research into clinical data and SEC filings.
Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving Average - Here's What Happened
Fate Therapeutics (NASDAQ:FATE) stock crossed above its 50-day moving average on Monday, trading as high as $1.2150. The clinical-stage biopharmaceutical company has a market cap of $137.3 million and a consensus analyst rating of "Hold" with a target price of $3.92. Recent analyst activity shows a mix of downgrades, upgrades, and reiterations, reflecting varied opinions on the stock.
Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 6.3% over the previous year
Institutional investors own 63% of Fate Therapeutics, Inc., a significant stake that makes the stock price sensitive to their trading actions. Despite a 6.3% loss over the past year, these investors likely appreciate the recent US$16 million market cap gain. The top 10 shareholders hold 51% of the company, and hedge funds account for 11% ownership, while insiders own a relatively small US$1.8 million worth of stock and have been selling recently.
Insider Selling: Fate Therapeutics (NASDAQ:FATE) Insider Sells 10,589 Shares of Stock
Fate Therapeutics (NASDAQ:FATE) director Cindy Tahl recently sold 10,589 shares of the company's stock for approximately $11,224, reducing her total holdings to 387,081 shares. The biopharmaceutical company's shares are currently trading around $1.07, and it holds a market capitalization of $123.4 million. Analysts provide a mixed outlook with a consensus "Hold" rating and an average price target of $3.92, while institutional investors own about 97.5% of the stock.
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of "Hold" from Brokerages
Fate Therapeutics (NASDAQ:FATE) has received a consensus "Hold" rating from nine brokerages, with an average one-year target price of $3.92. Despite a negative P/E ratio and profitability metrics, the company recently reported earnings that slightly beat analyst expectations. Institutional ownership is notably high at 97.54%, with several major investors recently increasing their stakes.
